The health technology firm is proposing a new software solution that would standardize coding in genetic testing, but a more predictable system would also narrow variability in test pricing.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The San Francisco-based medical genetics firm generated $53.5 million in revenues in the second quarter, beating analysts' consensus estimate of $50.7 million.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The company is hoping to add outreach to make sure individuals who want counseling get it, and to better understand the reasons why others might not.
Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Invitae said this week that it completed its acquisition of Singular Bio on June 19.
Senators said they'll narrow the draft bill containing changes to US patent law before submitting it to the Senate Judiciary Committee in July.
The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.
A Minnesota toddler given a gene therapy to treat her spinal muscular atrophy is now walking, according to Newsweek.
NBC Bay Area reports a California lab has been certified to conduct forensic mitochondrial DNA sequencing.
The New York Times reports on how environmental DNA sampling could monitor endangered species.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.